MedinCell S.A. (EPA:MEDCL)
France
· Delayed Price · Currency is EUR | Market Cap | 854.52M |
| Revenue (ttm) | 32.44M |
| Net Income (ttm) | -19.95M |
| Shares Out | 35.90M |
| EPS (ttm) | -0.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90,648 |
| Average Volume | 88,818 |
| Open | 23.52 |
| Previous Close | 23.80 |
| Day's Range | 22.74 - 23.64 |
| 52-Week Range | 14.50 - 39.68 |
| Beta | 0.98 |
| RSI | 47.30 |
| Earnings Date | Jun 16, 2026 |
About MedinCell
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults; and mdc-CWM, a sustained-release formulation of celecoxib in Phase III tria... [Read more]
Financial Performance
In fiscal year 2025, MedinCell's revenue was 27.73 million, an increase of 132.12% compared to the previous year's 11.95 million. Losses were -18.44 million, -26.36% less than in 2024.
Financial StatementsNews
Medincell to Host an Online R&D Day on Tuesday, May 12, 2026
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) will host an online R&D Day, held in English, on Tuesday, May 12, 2026, from 4:00 to 5:30 pm CEST (10:00 - 11:3...
Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatme...
FDA Accepts NDA For Teva And Medincell's Olanzapine LAI In Schizophrenia Treatment
(RTTNews) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), together with Medincell, announced that the U.S. Food and Drug Administration (FDA) has accepted its...
Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%)
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell's (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the following information in connection with the publication of its Q4 and ...
MedinCell Transcript: H1 25/26
Olanzapine LAI FDA filing and UZEDY's strong growth drive a 50% revenue increase and improved operating loss. The pipeline advances with AbbVie and Gates Foundation-backed programs, while a robust cash position supports future growth.
MedinCell Transcript: Evercore ISI 8th Annual HealthCONx Conference
Strong growth is expected from UZEDY and the upcoming long-acting olanzapine, which addresses key safety and compliance issues. Market adoption of LAIs is accelerating, with significant commercial potential in both the US and Europe.
MedinCell Transcript: Jefferies London Healthcare Conference 2025
A transformative period is underway, with strong UZEDY sales, a robust pipeline led by long-acting olanzapine, and global health initiatives. Profitability is targeted for 2027, with new technologies and partnerships fueling future growth.
Teva : FDA Grants Expanded Approval For UZEDY To Treat Bipolar I Disorder In Adults
(RTTNews) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), in collaboration with Medincell (MEDCL.PA), announced that the U.S. Food and Drug Administration has...
Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed
(RTTNews) - Medincell SA (MEDCL.PA) reported that new long-term safety data from the completed Phase 3 SOLARIS trial support the potential of Olanzapine LAI (TEV-749) as the first long-acting olanzapi...
MedinCell Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Three growth engines—UZEDY, olanzapine LAI, and a robust R&D pipeline—are driving rapid expansion, with UZEDY showing strong sales and real-world impact. Major partnerships and a strengthened financial position support a path to profitability by 2027.
MedinCell Transcript: H2 24/25
Revenue tripled to EUR 25.4 million and losses halved, driven by Uzedy's strong launch and pipeline progress. Patent protection was extended, cash reserves strengthened, and operational profitability is targeted for 2027, with major growth expected from Olanzapine LAI.
MedinCell Transcript: Jefferies Global Healthcare Conference 2025
BEPO technology is driving rapid growth in long-acting injectables, with UZEDY and olanzapine LAI leading a robust pipeline. Strategic partnerships, strong financials, and new programs in contraception and malaria position the company for significant royalty and revenue expansion.
MedinCell Transcript: TD Cowen 45th Annual Healthcare Conference
Long-acting injectable products, led by UZEDY, are driving rapid revenue growth and market share, with strong commercial performance and a robust pipeline supported by major partnerships. Technology advancements and new indications, including bipolar disorder, are set to expand future opportunities.
MedinCell Transcript: H1 24/25
Revenues grew 23% to €8.6M, driven by UZEDY royalties and AbbVie collaboration. Strong cash position and reduced losses support confidence in reaching operating profitability by FY 2026–2027, with major product and partnership milestones ahead.
MedinCell Transcript: H2 23/24
2023-2024 was transformative, highlighted by UZEDY's launch, a major AbbVie deal, and reduced net loss. Strong cash position, high-margin revenues, and robust pipeline support a path to profitability by 2026-2027.